Xagrid (anagrelide) – Package leaflet - L01XX35

Updated on site: 10-Oct-2017

Medication nameXagrid
ATC CodeL01XX35
ManufacturerShire Pharmaceutical Contracts Limited

Package leaflet: Information for the patient

Xagrid 0.5 mg hard capsules anagrelide

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Keep this leaflet. You may need to read it again.

If you have further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1.What Xagrid is and what it is used for

2.What you need to know before you take Xagrid

3.How to take Xagrid

4.Possible side effects

5.How to store Xagrid

6.Contents of the pack and other information

1.What Xagrid is and what it is used for

Xagrid contains the active substance, anagrelide. Xagrid is a medicine which interferes with the development of platelets. It reduces the number of platelets produced by the bone marrow, which results in a decrease in the platelet count in the blood towards a more normal level. For this reason it is used to treat patients with essential thrombocythaemia.

Essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets. Large numbers of platelets in the blood can cause serious problems with blood circulation and clotting.

2. What you need to know before you take Xagrid

Do not take Xagrid

If you are allergic to anagrelide or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may be recognised as a rash, itching, swollen face or lips, or shortness of breath;

If you have moderate or severe liver problems;

If you have moderate or severe kidney problems.

Warnings and precautions

Talk to your doctor before taking Xagrid:

If you have or think you might have a problem with your heart;

If you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), or you are taking other medicines that result in abnormal ECG changes or if you have low levels of electrolytes e.g. potassium, magnesium or calcium (see section “Other medicines and Xagrid”);

If you have any problems with your liver or kidneys.

In combination with acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin), there is an increased risk of major haemorrhages (bleeding) (see section “Other medicines and Xagrid”).

Children and adolescents

There is limited information on the use of Xagrid in children and adolescents and therefore this medicine should be used with caution.

Other medicines and Xagrid

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.

Tell your doctor if you are taking any of the following medicines:

Medicines that can alter your heart rhythm e.g. sotalol, amiodarone;

Fluvoxamine, used to treat depression;

Certain types of antibiotic, such as enoxacin, used to treat infections;

Theophylline, used to treat severe asthma and breathing problems;

Medicines used to treat heart disorders, for example, milrinone, enoximone, amrinone, olprinone and cilostazol;

Acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower fever, as well as to prevent blood clotting, also known as aspirin);

Other medicines used to treat conditions affecting the platelets in your blood, e.g. clopidogrel;

Omeprazole, used to reduce the amount of acid produced in the stomach;

Oral contraceptives: If you experience bad diarrhoea whilst taking this medicine, it may reduce how well the oral contraceptive works and use of an extra method of contraception is recommended (e.g condom). See the instructions in the patient leaflet of the contraceptive pill you are taking.

Xagrid or these medicines may not work properly if taken together.

If you are not sure, speak to your doctor or pharmacist for advice.

Pregnancy and breast-feeding

Tell your doctor if you are pregnant or are planning to become pregnant. Xagrid should not be taken by pregnant women. Women who are at risk of becoming pregnant should make sure that they are using effective contraception when taking Xagrid. Speak to your doctor if you need advice with contraception.

Tell your doctor if you are breast-feeding or if you are planning to breast-feed your baby. Xagrid should not be taken while breast-feeding. You must stop breast-feeding if you are taking Xagrid.

Driving and using machines

Dizziness has been reported by some patients taking Xagrid. Do not drive or use machines if you feel dizzy.

Xagrid contains lactose

Lactose is an ingredient in this medicine. If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.

3.How to take Xagrid

Always take Xagrid exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The amount of Xagrid that people take can be different, and this depends on your condition. Your doctor will prescribe the best dose for you.

The usual starting dose of Xagrid is 1 mg. You take this dose as one capsule of 0.5 mg twice a day, for at least a week. After this time, your doctor may either increase or decrease the number of capsules that you take to find the dose best suited to you and which treats your condition most effectively.

Your capsules should be swallowed whole with a glass of water. Do not crush the capsules or dilute the contents in a liquid. You can take the capsules with food or after a meal or on an empty stomach. It is best to take the capsule(s) at the same time every day.

Do not take more capsules than your doctor has recommended.

Your doctor will ask you to have blood tests at regular intervals to check that your medicine is working effectively and that your liver and kidneys are working well.

If you take more Xagrid than you should

If you take more Xagrid than you should or if someone else has taken your medicine, tell a doctor or pharmacist immediately. Show them the pack of Xagrid.

If you forget to take Xagrid

Take your capsules as soon as you remember. Take your next dose at the usual time. Do not take a double dose to make up for a forgotten dose.

4.Possible side effects

Like all medicines, Xagrid can cause side effects, although not everybody gets them. If you are worried, speak to your doctor.

Serious side effects:

Uncommon: Heart failure (signs include shortness of breath, chest pain, swelling of the legs due to fluid build-up), severe problem with the rate or rhythm of the heart beat (ventricular tachycardia, supraventricular tachycardia or atrial fibrillation), inflammation of the pancreas which causes severe abdominal and back pain (pancreatitis), vomiting blood or passing bloody or black stools, severe reduction in blood cells which can cause weakness, bruising, bleeding or infections (pancytopenia), pulmonary hypertension (signs include shortness of breath, swelling in legs or ankles, and lips and skin can turn bluish colour) .

Rare: Kidney failure (when you pass little or no urine), heart attack.

If you notice any of these side effects, contact your doctor immediately.

Very common side effects: may affect more than 1 in 10 people


Common side effects: may affect up to 1 in 10 people

Dizziness, tiredness, rapid heart beat, irregular or strong heartbeat (palpitations), feeling sick (nausea), diarrhoea, stomach pain, wind, being sick (vomiting), reduction in red blood cell count (anaemia), fluid retention or rash.

Uncommon side effects: may affect up to 1 in 100 people

A feeling of weakness or feeling unwell, high blood pressure, irregular heart beat, fainting, chills or fever, indigestion, loss of appetite, constipation, bruising, bleeding, swelling (oedema), weight loss, muscle aches, painful joints, back pain, decreased or loss of feeling or sensation such as numbness, especially in the skin, abnormal feeling or sensation such as tingling and ‘pins and needles’, sleeplessness, depression, confusion, nervousness, dry mouth, loss of memory, breathlessness, nosebleed, serious lung infection with fever, shortness of breath, cough, phlegm; hair loss, skin itching or discolouration, impotence, chest pain, reduction in blood platelets, which increases the risk of bleeding or bruising (thrombocytopenia), accumulation of fluid around the lungs or an increase in liver enzymes. Your doctor may do a blood test which may show an increase in your liver enzymes.

Rare side effects: may affect up to 1 in 1,000 people

Bleeding gums, weight gain, severe chest pain (angina pectoris), heart muscle disease, (signs include fatigue, chest pain and palpitations), enlarged heart, accumulation of fluid around the heart, loss of coordination, difficulty in speaking, dry skin, migraine, visual disturbances or double vision, ringing in the ears, dizziness on standing up (especially when getting up from a sitting or lying position), increased need to pass water at night, pain, ‘flu-like’ symptoms, sleepiness, widening of blood vessels, inflammation of the large bowel (signs include: diarrhoea, usually with blood and mucus, stomach pain, fever), inflammation of the stomach (signs include: pain, nausea, vomiting), area of abnormal density in the lung, increased creatinine level in blood tests, which may be a sign of kidney problems.

The following side effects have been reported but it is not known exactly how often they occur:

Potentially life-threatening, irregular heart beat (torsade de pointes);

Inflammation of the liver, symptoms include nausea, vomiting, itching, yellowing of the skin and eyes, discoloration of stool and urine (hepatitis);

Lung inflammation (signs include fever, coughing, difficulty breathing, wheezing; which causes scaring of the lungs) (allergic alveolitis, including interstitial lung disease, pneumonitis);

Inflammation of the kidneys (tubulointerstitial nephritis).

Reporting of side effects

If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not

listed in this leaflet. You can also report side effects directly via the national reporting system listed in

Appendix V. By reporting side effects you can help provide more information on the safety of this


5.How to store Xagrid

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

If your doctor stops your medicine, do not keep any leftover capsules unless your doctor tells you to. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Xagrid contains

The active substance is anagrelide. Each capsule contains 0.5 mg anagrelide (as anagrelide hydrochloride).

The other ingredients are:

Capsule contents: povidone (E1201); crospovidone; lactose, anhydrous; lactose monohydrate; cellulose, microcrystalline (E460) and magnesium stearate.

Capsule shell: gelatin and titanium dioxide (E171).

Printing ink: shellac; strong ammonium solution; potassium hydroxide (E525); black iron oxide (E172).

What Xagrid looks like and contents of the pack

Xagrid is supplied as opaque, white, hard capsules. They are marked with ‘S 063’.

The capsules are provided in bottles containing 100 hard capsules. The bottle also contains a small sealed container. This contains a drying agent to keep the capsules dry. Keep the sealed container in the bottle. Do not remove or eat the drying agent.

Marketing Authorisation Holder

Shire Pharmaceutical Contracts Limited

Hampshire International Business Park

Chineham, Basingstoke


RG24 8EP

United Kingdom

Tel: +44(0) 1256 894 000

Fax: +44(0) 1256 894 708

Email: medinfoemea@shire.com


Wasdell Packaging Limited

Units 1, 2, 3, 5, 6, 7 & 8 Euro Way Industrial Estate




United Kingdom

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

България, Hrvatska, Latvija, Lietuva, Magyarország, România, Slovenija, Slovenská republika

Shire Pharmaceuticals Ltd Великобритания, Lielbritānija, Jungtinė Karalystė, Nagy-Britannia, Marea Britanie, Velika Britanija, Vel’ká Británia

Teл/Tel: +44(0) 800 055 6614 email: medinfoemea@shire.com




Shire Italia S.p.A

Shire Belgium BVBA

Tel: +39 0265 535 096


email: medinfoemea@shire.com

Tél/Tel: +32 (0)2711 0246


email: medinfoemea@shire.com


Česká Republika


Shire Pharmaceuticals Ltd

Shire Hellas S.A

Velká Británie


Tel: +420 239 018 556

Τηλ: +30 216 900 4026

email: medinfoemea@shire.com

email: medinfoemea@shire.com



Shire Sweden AB

Vivian Corporation Ltd


Tel: +356 21 320338

Tlf: + 45 (0)80 886 962

email: medinfoemea@shire.com

email: medinfoemea@shire.com




Shire Deutschland GmbH

Shire Belgium BVBA

Tel: +49 (0)800 1830742


email: medinfoemea@shire.com

Tel: +31 (0)2020 35492


email: medinfoemea@shire.com



Grove Healthcare Baltic UAB

Shire Sweden AB



Tel: +372 55596234

Tlf: +47 800 19240

email: medinfoemea@shire.com

email: medinfoemea@shire.com



Shire Hellas S.A

Shire Pharmaceuticals Ltd

Τηλ: +30 216 900 4026

Wielka Brytania

email: medinfoemea@shire.com

Tel: +48 (0)2230 62447


email: medinfoemea@shire.com



Shire Pharmaceuticals Ibérica, S.L.

Shire Austria GmbH

Tel: +34 900 947 618 (Toll-Free number)

Tel: +43 (0)120 609 2538

When using mobile phone dial +34 91 422 9896

email: medinfoemea@shire.com

email: medinfoemea@shire.com




Shire France S.A.

Shire Pharmaceuticals Portugal Lda

Tél: +33 (0)800 907 913

Tel: +351 800 785 005

Outside France dial +33(0)1 40 67 32 90

email: medinfoemea@shire.com

email: medinfoemea@shire.com




Shire Pharmaceuticals Ltd

Shire Sweden AB

United Kingdom


Tel: 1800 818 016

Puh/Tel: + 358 (0)800 774 051

Outside Ireland dial +44 800 055 6614

email: medinfoemea@shire.com

email: medinfoemea@shire.com




Shire Sweden AB

Shire Sweden AB


Tel: 020-795 079

Sími: +46 8 544 964 00

Outside Sweden dial +46 8 544 964 00

email: medinfoemea@shire.com

email: medinfoemea@shire.com

United Kingdom

Shire Pharmaceuticals Ltd Tel: 0800 055 6614

email: medinfoemea@shire.com

This leaflet was last revised in 06/2017.

This medicine has been authorised under “exceptional circumstances”. This means that because of the rarity of this disease it has been impossible to get complete information on this medicine.

The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.




Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for anagrelide, the scientific conclusions of CHMP are as follows:

During the reporting period, nine new cases were retrieved through the search with the SMQ for pulmonary hypertension, all serious. Pulmonary hypertension is part of the known safety profile for anagrelide, currently listed in section 4.8 of the SmPC as a ‘rare’ adverse reaction.

Based on the updated total of 35 cases of pulmonary hypertension retrieved from the clinical trials cumulatively, all assessed as unrelated to the underlying treated disease of essential thrombocythaemia, the reporting frequency for pulmonary hypertension from evaluable clinical trials was recalculated as 35/5578 = 0.0063 (0.63%), which corresponds to an ‘uncommon’ event. Considering the nine new cases suggesting a causal relationship with anagrelide together with the recalculated reporting frequency, a change in frequency from ‘rare’ to ‘uncommon’ is considered appropriate. The change should be implemented accordingly in the package leaflet.

Moreover, these new cases and the higher frequency of occurrence also raise the need for further information to be provided in section 4.4 of the SmPC, in order to alert healthcare professionals to this serious adverse reaction and the need for close monitoring of the patients for any symptom of pulmonary hypertension, including in patients with a medical history of pulmonary hypertension. The package leaflet should be updated accordingly.

As Xagrid and Thromboreductin contain the same active substance, with similar therapeutic schemes, the safety profile for this risk is expected to be similar, despite lower reporting with Thromboreductin and the PRAC therefore considered that the changes to the product information should be implemented for both products.

The CHMP agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the marketing authorisation(s)

On the basis of the scientific conclusions for anagrelide the CHMP is of the opinion that the benefit- risk balance of the medicinal product(s) containing anagrelide is unchanged subject to the proposed changes to the product information

The CHMP recommends that the terms of the marketing authorisation(s) should be varied.


  • Help
  • Get it on Google Play
  • About
  • Info on site by:

  • Presented by RXed.eu

  • 27558

    prescription drugs listed